INVO Bioscience Executives
INVODelisted Stock | USD 0.84 0.03 3.45% |
INVO Bioscience employs about 25 people. The company is managed by 10 executives with a total tenure of roughly 59 years, averaging almost 5.0 years of service per executive, having 2.5 employees per reported executive. Analysis of INVO Bioscience's management performance can provide insight into the firm performance.
INVO |
INVO Bioscience Management Team Effectiveness
The company has return on total asset (ROA) of (0.2657) % which means that it has lost $0.2657 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (143.5864) %, meaning that it created substantial loss on money invested by shareholders. INVO Bioscience's management efficiency ratios could be used to measure how well INVO Bioscience manages its routine affairs as well as how well it operates its assets and liabilities.INVO Bioscience Workforce Comparison
INVO Bioscience is currently regarded as number one stock in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 3,377. INVO Bioscience maintains roughly 25.0 in number of employees contributing less than 1% to equities under Health Care industry.
The company has Profit Margin (PM) of (1.23) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.04) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.04. INVO Bioscience Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific INVO Bioscience insiders, such as employees or executives, is commonly permitted as long as it does not rely on INVO Bioscience's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, INVO Bioscience insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Andrea Goren over two months ago Disposition of tradable shares by Andrea Goren of INVO Bioscience subject to Rule 16b-3 | ||
Messina Rebecca over three months ago Acquisition by Messina Rebecca of 9868 shares of INVO Bioscience at 0.95 subject to Rule 16b-3 | ||
Davis Trent D over three months ago Acquisition by Davis Trent D of 11184 shares of INVO Bioscience at 0.95 subject to Rule 16b-3 | ||
Ryan Barbara over six months ago Insider Trading | ||
Ryan Barbara over six months ago Acquisition by Ryan Barbara of 10435 shares of INVO Bioscience subject to Rule 16b-3 | ||
Shum Steve over a year ago Acquisition by Shum Steve of 200000 shares of INVO Bioscience subject to Rule 16b-3 | ||
Ranoux Claude over a year ago Sale by Ranoux Claude of 500000 shares of INVO Bioscience | ||
Ryan Barbara over a year ago Acquisition by Ryan Barbara of 85000 shares of INVO Bioscience subject to Rule 16b-3 |
INVO Bioscience Notable Stakeholders
An INVO Bioscience stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as INVO Bioscience often face trade-offs trying to please all of them. INVO Bioscience's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting INVO Bioscience's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Michael Campbell | COO Development | Profile | |
Kevin MD | Medical Director | Profile | |
FACS FACOG | VP Integration | Profile | |
Bojan Mitrovic | Director US | Profile | |
Lori MarzilliKahler | VP Operations | Profile | |
Terah Krigsvold | Controller | Profile | |
Chris Myer | Sr Americas | Profile | |
Steven Shum | CEO Director | Profile | |
Andrea Goren | Chief Officer | Profile | |
Robert Bowdring | Treasurer Secretary | Profile |
About INVO Bioscience Management Performance
The success or failure of an entity such as INVO Bioscience often depends on how effective the management is. INVO Bioscience management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of INVO management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the INVO management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
INVO Bioscience, Inc., a commercial-stage fertility company, provides assisted reproductive technology solutions worldwide. The company was founded in 2007 and is based in Sarasota, Florida. Invo Bioscience operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 10 people.
INVO Bioscience Workforce Analysis
Traditionally, organizations such as INVO Bioscience use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare INVO Bioscience within its industry.INVO Bioscience Manpower Efficiency
Return on INVO Bioscience Manpower
Revenue Per Employee | 120.8K | |
Revenue Per Executive | 302.1K | |
Net Loss Per Employee | 321.4K | |
Net Loss Per Executive | 803.5K |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Other Consideration for investing in INVO Stock
If you are still planning to invest in INVO Bioscience check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the INVO Bioscience's history and understand the potential risks before investing.
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Bonds Directory Find actively traded corporate debentures issued by US companies |